Research and Markets: The Russian Pharmaceutical Market is Anticipated to Grow at a CAGR of Around 11% During 2012-2017
Print 24 December 2013
December 18, 2013 DUBLIN — Research and Markets has announced the addition of the "Russian Pharmaceutical Market Outlook to 2017" report to their offering. The pharmaceutical industry in Russia finally seems ready for a change. With the government adopting Strategy 2020' to improve the production capacity of the Russian pharma sector, pharmaceutical companies have started investing in the Russian market.
As a result, the Russian pharmaceutical industry has started growing at a steady rate. In future, various factors such as increased support from the government, rise in expenditure on healthcare, and noteworthy growth in investments made by the private players will continue to boost the market.
According to the report, Russian Pharmaceutical Market Outlook to 2017, the pharmaceutical market is anticipated to grow at a CAGR of around 11% during 2012-2017. Essentially, this report provides an exhaustive study of the Russian pharmaceuticals market. A section has been dedicated to the industry's infrastructure which focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market.
The market has been segmented as per various levels such as the state segment, the commercial segment and the parapharmaceutical segment. Subsequently, markets for these segments have been further broken down on the basis of their ATC groups. The drugs import scenario for each segment has also been provided. Moreover, major distributors of the pharmaceutical industry have been highlighted along with their respective market shares.
The report provides an insight into the clinical trial scenario and reveals that almost twice the number of clinical trials has been approved in 2012 as compared to 2011. This is indicative of the increasing government support in order to boost domestic innovation. Further, current market driving forces and roadblocks have been discussed. On the one hand, increasing support from the government can be seen as a ray of hope for providing the market a necessary boost, while on the other corruption, deep rooted at every level, may act as a deterrent.
The report also focuses on the current regulatory reforms such as the transition to GMP standards, promotion, and procurement of pharmaceuticals which will play important roles in sculpting the market. Lastly, detailed analysis of major pharmaceutical players within Russia has been given with emphasis on strengths and weaknesses as well as the recent developments of each player.
About Research and Markets
According to the report, Russian Pharmaceutical Market Outlook to 2017, the pharmaceutical market is anticipated to grow at a CAGR of around 11% during 2012-2017. Essentially, this report provides an exhaustive study of the Russian pharmaceuticals market. A section has been dedicated to the industry's infrastructure which focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market.
The market has been segmented as per various levels such as the state segment, the commercial segment and the parapharmaceutical segment. Subsequently, markets for these segments have been further broken down on the basis of their ATC groups. The drugs import scenario for each segment has also been provided. Moreover, major distributors of the pharmaceutical industry have been highlighted along with their respective market shares.
The report provides an insight into the clinical trial scenario and reveals that almost twice the number of clinical trials has been approved in 2012 as compared to 2011. This is indicative of the increasing government support in order to boost domestic innovation. Further, current market driving forces and roadblocks have been discussed. On the one hand, increasing support from the government can be seen as a ray of hope for providing the market a necessary boost, while on the other corruption, deep rooted at every level, may act as a deterrent.
The report also focuses on the current regulatory reforms such as the transition to GMP standards, promotion, and procurement of pharmaceuticals which will play important roles in sculpting the market. Lastly, detailed analysis of major pharmaceutical players within Russia has been given with emphasis on strengths and weaknesses as well as the recent developments of each player.
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.